This tease is from Tim Field's "Untapped Wealth":

At $4, this is a dream stock at a bargain price that could be the most profitable investment of your entire lifetime. Even the  federal government says the Genetic Diagnostics industry ‘PROMISES TO REVOLUTIONIZE MEDICINE.’

With the gene-based Multiplex test (the detection of multiple targets simultaneously from a single sample)our phantom diagnostics stock has developed, this figure could be cut down to almost nothing. The idea behind this miracle is simple: by knowing what your genetic makeup is, your doctor will be better able to match you up with the most effective drug before you take it. No guessing, no taking chances, practically ZERO side effects.

Going after some of the biggest diseases known to mankind, the company is developing diagnostic tests for cancer, neurodegenerative, cardiovascular, and infectious diseases, as well as pharmaco-genetics or tests for personalized medicine.

It is also developing tests for genomic assays, including hyper-coagulation, warfarin metabolism, cystic fibrosis, herpes simplex virus, human papillomavirus, and respiratory virus panel; and protein assays, such as prostate specific antigen, cardiac troponin, and biomarker validation.

Their patent portfolio is comprised, on a worldwide basis, of 80 issued patents and 150 pending patent applications, which, they either own directly or are the exclusive licensee.

The President and CEO has over 30 years experience in the diagnostics and medical devices industry and spent the last 20 developing novel technologies into products and solutions that have helped shape the industry and create shareholder value.

     But how profitable has his work and experience been?

     In his previous venture, he served as president and CEO for a developer, manufacturer and marketer of diagnostic products that pioneered the point-of-care blood analysis market.

This pioneer led them from its early stage to commercialization and then from the company's IPO in 1992 to its acquisition in 2003 for 5.18 times revenues or $392 million.

But it doesn’t stop there…

From 1973 through 1989 he held executive positions with a $7 billion manufacturer and distributor of healthcare products and a $3.5 billion diversified manufacturer and distributor of healthcare products. How about his team?

     The VP of Sales and Marketing and Chief Marketing Officer has more than 17 years of sales and marketing experience in the medical device industry.

Prior to his current position he spent 13 years of leadership roles in marketing and strategic development. Most recently, he served as the vice president of marketing, a $700 million division, of a $4.3 billion medical technology company.

Then there is the Vice President of International Sales and Marketing who has more than 21 years of healthcare experience in clinical diagnostics, medical devices and information technology with Fortune 500 companies such as Baxter, American Scientific Products, Allegiance Healthcare and two start-up technology companies.

Before joining the team in January 2002, he served as General Manager for Allegiance Healthcare with P&L responsibility for a $120 million revenue base.

I know this is not much to go on, but does anyone have any ideas?

Thanks in advance.